doi:https://doi.org/

References:

Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2008;133:Suppl:454S-545S. [Erratum, Chest 2008;134:892.]
Ost D., Tepper J., Mihara H., et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005;294:706-715.
Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
Schulman S., Kakkar A.K., Schellong S.M., et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Presented at the American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011. abstract.
Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907. [Erratum, N Engl J Med 1999; 341:298.]
Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.
Agnelli G., Prandoni P., Becattini C., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
Agnelli G., Prandoni P., Santamaria M.G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169.
Schulman S., Granqvist S., Holmstrom M., et al. The duration of oral anticoagulant therapy after a second episode of ve- nous thromboembolism. N Engl J Med 1997;336:393-398.
Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
Schulman S., Wahlander K., Lundstrom T., et. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510.
Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in pa- tients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. [Erratum, N Engl J Med 2010;363:1877.]
Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-676.
Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.